Form 8-K - Current report:
SEC Accession No. 0001615219-22-000003
Filing Date
2022-01-13
Accepted
2022-01-13 16:05:50
Documents
15
Period of Report
2022-01-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K flks-20220112.htm   iXBRL 8-K 46986
2 EX-10.1 salarius-deuterxacquisitio.htm EX-10.1 574874
3 EX-99.1 salariusdeuterxdealpressre.htm EX-99.1 27897
7 image_0a.jpg GRAPHIC 111802
  Complete submission text file 0001615219-22-000003.txt   1050312

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT flks-20220112.xsd EX-101.SCH 1924
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT flks-20220112_lab.xml EX-101.LAB 23892
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT flks-20220112_pre.xml EX-101.PRE 12541
9 EXTRACTED XBRL INSTANCE DOCUMENT flks-20220112_htm.xml XML 11337
Mailing Address 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021 346-772-0346
Salarius Pharmaceuticals, Inc. (Filer) CIK: 0001615219 (see all company filings)

EIN.: 465087339 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36812 | Film No.: 22529140
SIC: 2834 Pharmaceutical Preparations